Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Ausun Pharmaceutical CoSHSE:603229 -2.99%82 ROC (Joel Greenblatt) % is 31.66% as of Mar. 2026, which is 13% above its 10-year median of 28.11. GuruFocus rates SHSE:603229 with a GF Score™ of 82/100 and a GF Value™ of ¥10.48 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 1,325 Biotechnology companies, Zhejiang Ausun Pharmaceutical Co ranks better than 82.49% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Zhejiang Ausun Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 31.66%.
The historical rank and industry rank for Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:603229'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.5 Med: 28.11 Max: 43.58
Current: 8.5
During the past 13 years, Zhejiang Ausun Pharmaceutical Co's highest ROC (Joel Greenblatt) % was 43.58%. The lowest was 8.50%. And the median was 28.11%.
SHSE:603229's ROC (Joel Greenblatt) % is ranked better than 82.49% of 1325
companies
in the Biotechnology industry
Industry Median: -306.8
vs SHSE:603229: 8.50
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Ausun Pharmaceutical Co ROC (Joel Greenblatt) % Chart
SHSE:603229 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) % falls into.
Zhejiang Ausun Pharmaceutical Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 31.66% mean?
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a ROC (Joel Greenblatt) % of 31.66% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. This is 13% above median its historical median of 28.11. Over the past decade, Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) % has ranged from 8.50 to 43.58. According to the industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #232 out of 1325 companies in the Biotechnology industry, placing it in the top 17.5%.
Is Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) % too high?
Zhejiang Ausun Pharmaceutical Co's current ROC (Joel Greenblatt) % of 31.66% is 13% above median its 10-year median of 28.11. Over the past 10 years, this metric has ranged from a low of 8.50 to a high of 43.58. Based on the distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #232 out of 1325 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #232 out of 1325 companies for ROC (Joel Greenblatt) %. This places Zhejiang Ausun Pharmaceutical Co in the top 18% of its industry — outperforming the majority of peers. Historically, Zhejiang Ausun Pharmaceutical Co's own ROC (Joel Greenblatt) % has ranged from 8.50 to 43.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. Zhejiang Ausun Pharmaceutical Co's current ROC (Joel Greenblatt) % is 31.66%, which is 13% above median its own 10-year median of 28.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.48, compared to a current price of ¥8.10 — trading 22.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 31.66%, which is 13% above median its 10-year median of 28.11. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current ROC (Joel Greenblatt) % is 31.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.10 is trading 22.7% below its estimated GF Value™ of ¥10.48.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
ROC (Joel Greenblatt) %: 31.66% (13% above median its 10-year median of 28.11)
GF Value™: ¥10.48 vs. price of ¥8.10 (22.7% below fair value)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
82GF Score
Get the complete analysis for SHSE:603229
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
